Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

A pharmaceutical composition comprising

• an aqueous carrier;
• from 0.1 mg/ml to 20 mg/ml of the composition of an acetate salt of a peptide having the structural formula
• NH2-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH (SEQ ID NO:1);
• and
• from 70 mg/ml to 170 mg/ml of the composition of hepta-(sulfobutyl ether)-β-cyclodextrin,
• wherein the peptide and the hepta-(sulfobutyl ether)-β-cyclodextrin are dissolved in the aqueous carrier;
• and
• wherein the composition has a pH between 6.5 and 8.5.

A lyophilized pharmaceutical composition comprising

• a pharmaceutically acceptable salt of a peptide having the structural formula
• NH2-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH (SEQ ID NO:1);
• and
• a substituted β-cyclodextrin.